Bristol-Myers Squibb (BMS) is a major producer of therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. The medicines business consists of worldwide pharmaceuticals and consumer medicines. 
While BMS experienced the negative impact of generic competition in its pharmaceutical business, it says that it was successful in launching several new products, expanding key businesses and advancing its pipeline. As a result, BMS says that it is now well positioned to begin growing sales and earnings, and to build shareholder value.
The company will continue to execute its strategy for long term growth by increasing investments behind growth drivers and focusing the company's research and development programmes on products that address significant unmet medical needs.
Bristol-Myers Squibb operates in more than 60 countries, has 41,000 employees and net sales of around $20.5bn in 2008.
ICIS Chemical Business magazine has unveiled the ICIS Top 100 Chemical Companies, with rankings based on 2008 sales.
A PDF of the ICIS Top 100 Chemical Companies is available for download on ICIS connect.
See the article and analysis of the ICIS Top 100 on ICIS news.
Key Personnel
Chairman and CEO: James Cornelius
Lead director: Lewis Campbell
Board member: Lamberto Andreotti
Board member: Louis Freeh
Board member: Laurie Glimcher
Board member: Michael Grobstein
Board member: Leif Johansson
Board member: Alan Lacy
Board member: Vicki Sato
Board member: Togo West
Board member: Sanders Williams
Executive board
Chairman and CEO: James Cornelius
Member: Lamberto Andreotti
Member: Elliott Sigal
Member: Jean-Marc Huet
(Updated March 2009)
Contacts
Bristol-Myers Squibb Company
World Headquarters
345 Park Avenue
New York, 10154-0037
US
Tel: +1 212 546 4000
Fax: +1 212 546 4020
www.bms.com
Bristol Myers Squibb
Company Structure
Bristol-Myers Squibb (BMS) operates in more than 60 countries around the globe. The company was formed through a merger in 1989, which at that time was considered to be one of the largest in corporate history. In October 2001, BMS further strengthened its medicines business with the acquisition of DuPont Pharmaceuticals. Today, Bristol-Myers Squibb is a diversified worldwide health and personal care company whose core businesses are medicines, nutrition (Mead Johnson) and medical devices (ConvaTec).
More about Bristol Myers Squibb Structure
Bristol Myers Squibb
Strategy & Financial Highlights
Bristol-Myers Squibb (BMS) will continue to execute its strategy for long term growth. Its strategy consists of increasing investments behind growth drivers, focusing the company's research and development programmes on products in the pharmaceutical pipeline in disease areas that address significant unmet medical needs, aligning sales and marketing emphasis on specialists and high value primary care prescribers, and implementing initiatives designed to achieve and maintain a more efficient cost base. ICIS also provides you with key financial data listed in table form.
More about Bristol Myers Squibb Strategy & Financial Highlights
News:
Get news on Bristol Myers Squibb plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Search:
Find details on other chemical companies and suppliers with
ICIS search
Newsletters:
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Plants and projects:
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database